5 results about "Chronic pain" patented technology

The invention relates to compounds, compositions, and methods for derepressing RE1 silencing transcription factor (REST) target genes are provided. In particular, a peptide having the sequence TEDLEPPEPPLPKEN (SEQ. ID NO: 1) and EDLEPPEPPLPK (SEQ. ID NO: 15), or the reversed sequences made of D-amino acids (retro inverted, RI) nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), are disclosed for inhibiting REST activity. The peptides are useful to treat, prevent, or ameliorate conditions such as traumatic brain injury, epilepsy, dementia, Huntington's Disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer; diabetes, and peripheral nerve injury

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

The present disclosure provides a use for preventing or treating chronic pain in a subject in need thereof, comprising administering to the subject an effective amount of Lactococcus lactis DSM 27109 composition.

The application discloses a kind of pharmaceutical composition, preparation and preparation method of treating fibromyalgia syndrome, it is related to chronic pain disease treatment technical field.The pharmaceutical composition includes white flesh lucid ganoderma polysaccharide, quercetin, hesperetin and naringenin.The application further discloses a kind of pharmaceutical preparation for treating fibromyalgia syndrome and preparation method thereof.The pharmaceutical composition can effectively solve the problems of poor effect, high recurrence rate and obvious side effects of existing fibromyalgia syndrome treatment drugs;The application uses natural product to be matched, side effect is small, and can significantly improve the improvement effect on the core symptom of fibromyalgia syndrome.

a. This application is being submitted to the U.S. Patent and Trademark Office for review, processing, and approval of the issuance of a Utility Nonprovisional Patent and Trademark of a ‘newly discovered non-obvious use’ of an existing material that can be utilized to alleviate chronic joint pains. This newly discovered non-pharmaceutical material, does not require FDA approval. When applied to the skin area of a human's painful joints the material has alleviated joint pain, helped to stabilize the joint, reduced swelling around the joint, and helped to promote joint healing. This discovery can help millions who suffer with chronic joint pains return to a productive life. This non-medicated, non-pharmaceutical commercial material when applied to the skin area of a painful joint has been used and tested successfully for two (2) to alleviate joint pain, as a chronic pain-management process. The material and ‘application process’ of the material has completely stop joint pain, and reduced swelling while helping to promote the joint healing process without medication in the human body.